Literature DB >> 17050253

Differentiation of umbilical cord blood-derived multilineage progenitor cells into respiratory epithelial cells.

M J Berger1, S D Adams, B M Tigges, S L Sprague, X-J Wang, D P Collins, D H McKenna.   

Abstract

BACKGROUND: Umbilical cord blood (UCB) has been examined for the presence of stem cells capable of differentiating into cell types of all three embryonic layers (i.e. endo-, ecto- and mesoderm). The few groups reporting success have typically confirmed endodermal potential using hepatic differentiation. We report differentiation of human UCB-derived multipotent stem cells, termed multilineage progenitor cells (MLPC), into respiratory epithelial cells (i.e. type II alveolar cells).
METHODS: Using a cell separation medium (PrepaCyte-MLPC; BioE Inc.) and plastic adherence, MLPC were isolated from four of 16 UCB units (American Red Cross) and expanded. Cultures were grown to 80% confluence in mesenchymal stromal cell growth medium (MSCGM; Cambrex BioScience) prior to addition of small airway growth medium (SAGM; Cambrex BioScience), an airway maintenance medium. Following a 3-8-day culture, cells were characterized by light microscopy, transmission electron microscopy, immunofluorescence and reverse transcriptase (RT)-PCR.
RESULTS: MLPC were successfully differentiated into type II alveolar cells (four of four mixed lines; two of two clonal lines). Differentiated cells were characterized by epithelioid morphology with lamellar bodies. Both immunofluorescence and RT-PCR confirmed the presence of surfactant protein C, a protein highly specific for type II cells. DISCUSSION: MLPC were isolated, expanded and then differentiated into respiratory epithelial cells using an off-the-shelf medium designed for maintenance of fully differentiated respiratory epithelial cells. To the best of our knowledge, this is the first time human non-embryonic multipotent stem cells have been differentiated into type II alveolar cells. Further studies to evaluate the possibilities for both research and therapeutic applications are necessary.

Entities:  

Mesh:

Year:  2006        PMID: 17050253     DOI: 10.1080/14653240600941549

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  41 in total

Review 1.  Transplantation of umbilical cord blood stem cells for treating spinal cord injury.

Authors:  Dong-Hyuk Park; Jeong-Hyun Lee; Cesario V Borlongan; Paul R Sanberg; Yong-Gu Chung; Tai-Hyoung Cho
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

2.  Delayed cord clamping: are we ready to listen to the doctor from 1796?

Authors:  G T Mandy
Journal:  J Perinatol       Date:  2016-01       Impact factor: 2.521

3.  Long-term research of stem cells in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Yun Luan; Xue Zhang; Tong-Gang Qi; Guang-Hui Cheng; Chao Sun; Feng Kong
Journal:  Clin Exp Med       Date:  2013-08-31       Impact factor: 3.984

Review 4.  Stem cells and cell therapies for cystic fibrosis and other lung diseases.

Authors:  Daniel J Weiss
Journal:  Pulm Pharmacol Ther       Date:  2007-12-07       Impact factor: 3.410

Review 5.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

Review 6.  Stem cell sources for vascular tissue engineering and regeneration.

Authors:  Vivek K Bajpai; Stelios T Andreadis
Journal:  Tissue Eng Part B Rev       Date:  2012-07-03       Impact factor: 6.389

Review 7.  Private cord blood banking: current use and clinical future.

Authors:  Peter Hollands; Catherina McCauley
Journal:  Stem Cell Rev Rep       Date:  2009-07-15       Impact factor: 5.739

8.  Umbilical cord blood processing using Prepacyte-CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation.

Authors:  C Basford; N Forraz; S Habibollah; K Hanger; C P McGuckin
Journal:  Cell Prolif       Date:  2009-09-15       Impact factor: 6.831

9.  miRNA-146a expression positively regulates tumor necrosis factor-α-induced interleukin-8 production in mesenchymal stem cells and differentiated lung epithelial-like cells.

Authors:  Diahn-warng Perng; De-ming Yang; Yi-han Hsiao; Ting Lo; Oscar Kuang-sheng Lee; Mo-tzu Wu; Yu-chung Wu; Yu-chin Lee
Journal:  Tissue Eng Part A       Date:  2012-09-24       Impact factor: 3.845

10.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.